Search
Erythropoietin
go.drugbank.com/drugs/DB00016ApprovedInvestigationalvarious clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures [FDA Label]. … It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced.
Products: EXETIN-A, EPO STADA 2000IU/0.6ml Solution for Injection in a Pre-filled SyringeAbemaciclib
go.drugbank.com/drugs/DB12001ApprovedInvestigationalAbemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity … It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with [DB00947].
Categories: MATE 1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexFidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigationalFidanacogene elaparvovec is a liver-specific adeno-associated virus (AAV) vector containing a codon-optimized human coagulation FIX gene that was investigated as a potential treatment for hemophilia B. … Current available treatments include substitution therapy involving the intravenous administration of standard factor IX once a week for bleeding or as prophylaxis and 2–3 times a week for severe hemophilia
EGS21
go.drugbank.com/drugs/DB05056ExperimentalGC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate … EGS21(TM) is a beta-D-glucosylceramide (GC) compound. It is a potential therapeutic for treating immune mediated disorders.
Naloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalNaloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. … It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain.
Categories: Compounds used in a research, industrial, or household settingEtoposide
go.drugbank.com/drugs/DB00773ApprovedInvestigationalA semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexTandamine
go.drugbank.com/drugs/DB09192ExperimentalTandamine was researched in 1970s as an antidepressant but was never commercialized. Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI).
Stannous chloride
go.drugbank.com/drugs/DB11056ApprovedStannous chloride is used as a source of tin in radiopharmaceutical kits. … Tin reduces technetium-99m, the active radiological agent, allowing it to form a complex with phosphate-containing moeities [A32700].
GT 389-255
go.drugbank.com/drugs/DB05894ExperimentalPeptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and … It is expected to block fat absorption with fewer side effects than currently marketed lipase inhibitors.
Meclofenamic acid
go.drugbank.com/drugs/DB00939ApprovedInvestigationalVet approvedA non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.